<DOC>
	<DOCNO>NCT00680992</DOCNO>
	<brief_summary>To determine safe denosumab treat subject giant cell tumor bone</brief_summary>
	<brief_title>Study Denosumab Subjects With Giant Cell Tumor Bone</brief_title>
	<detailed_description>To determine safe denosumab treat subject giant cell tumor bone</detailed_description>
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Giant Cell Tumor Bone</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Inclusion criterion : Pathologically confirm giant cell tumor bone within 1 year study enrollment Measurable evidence active disease within 1 year study enrollment Subjects surgically unsalvageable disease ( eg , sacral , spinal GCTB , multiple lesion include pulmonary metastasis ) OR subject whose plan surgery include joint resection , limb amputation , hemipelvectomy surgical procedure result severe morbidity Karnofsky performance status equal great 50 % Adults skeletally mature adolescent ( ie , radiographic evidence least 1 mature long bone [ eg , humerus close growth epiphyseal plate ] ) equal great 12 year age Skeletally mature adolescent must weigh least 45 kg Before studyspecific procedure perform , appropriate write informed consent must obtain Exclusion criterion : Currently receive GCTB specific treatment ( eg , radiation , chemotherapy , embolization ) Concurrent bisphosphonate treatment Known suspect current diagnosis underlying malignancy include high grade sarcoma , osteosarcoma , fibrosarcoma , malignant giant cell sarcoma Known suspect current diagnosis non GCTB giant cellrich tumor Known suspect current diagnosis brown cell tumor bone Paget 's disease Known diagnosis second malignancy within past 5 year Prior history current evidence osteonecrosis/osteomyelitis jaw Active dental jaw condition require oral surgery Nonhealed dental/oral surgery Planned invasive dental procedure course study Subject currently enrol yet complete least 30 day since end investigational device drug study ( ) , subject receive investigational agent ( ) Subject know sensitivity product administer dose Unstable systemic disease include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within 6 month enrollment Subject pregnant breast feeding , plan become pregnant within 5 month end treatment Female subject child bear potential willing use two method highly effective contraception treatment 5 month end treatment Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Giant Cell Tumor Bone</keyword>
</DOC>